Get to know our product ABTL0812 and its mechanism of action

September 06, 2018

From AbilityPharma we are pleased to announce that next September 12 our crowdfunding campaign #notwithoutyou will be officially opened through the company Capital Cell, a pioneering online investment platform in Europe specialized in biotechnology and health.
 
Today we would like to explain in more detail our drug ABTL0812 and its mechanism of action.
 
ABTL0812, is a "first-in-class" anticancer compound, administered orally. It binds to the PPAR α/γ receptor, causing the inhibition of the PI3K/AKT/mTOR metabolic pathway, which is modified in almost 50% of human cancers, and causing reticular stress of the cancer cells. The combination of TRIB3-mediated inhibition of the PI3K/Akt/mTOR pathway and the induction of ER-Stress results in cancer cell death mediated by autophagy (autodigestion), giving it great potential in different types of cancer.


LINK: https://youtu.be/QMYfLaSNyT0
 
At AbilityPharma we are convinced that we can make a difference in the fight against cancer since our drug so far has shown:
 
   - To be efective administered as a single therapy (monotherapy)
   - To increase the therapeutic effect (synergistic effect) of chemotherapy when the two treatments are combined, without increasing their toxicity
   - To be active in cells resistant to other therapies, active in tumor stem cells and has shown to inhibit the formation of metastasis
   - Possible combinations with immunotherapy to enhance its effect
 
Currently, our drug is in phase 2 clinical trials in patients with endometrial and lung cancer, in Spain and France, in combination with chemotherapy. After chemotherapy the drug ABTL0812 will continue to be administered as a chronic treatment in order to reduce the number of relapses to the disease.
 
The IND for clinical trials for pancreatic cancer is approved in the US, we plan to continue investigating other oncological indications such as the pediatric cancer neuroblastoma, cholangiocarcinoma, resistant breast cancer, head and neck cancer or glioblastoma.
  
Want to know more about us?
 
On the occasion of our crowfunding campaign #notwithoutyou, we have prepared a summary guide with the most important information of our company and our project, we invite you to download the guide here.

LATEST NEWS

12.09.2019

News

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG